Angiogenic growth factors in maternal and fetal serum in pregnancies complicated with intrauterine growth restriction
Autores de IIS La Fe
Grupos
Abstract
The aim of this paper was to study if soluble fms-like tyrosine kinase 1 (sFlt-1), free vascular endothelial growth factor (f-VEGF) and the f-VEGF/sFlt-1 quotient in singleton pregnancies complicated with intrauterine growth restriction (IUGR) are different from controls. This was a case-control study between 18 pregnancies with IUGR and 24 controls. Angiogenic growth factors were measured in maternal serum during pregnancy and in umbilical artery and vein at birth. Results showed that maternal plasma f-VEGF and s-Flt-1 were significantly higher in IUGR compared with controls (p = 0.01 and 0.001, respectively). f-VEGF/sFlt-1 quotient was significantly lower in the IUGR group compared with controls. When we analysed umbilical cord angiogenic factors, we found no significant differences in the artery or vein angiogenic growth factors between the IUGR group and controls. It was concluded that mothers of IUGR fetuses have a more anti-angiogenic environment compared to those of controls.
Datos de la publicación
- ISSN/ISSNe:
- 0144-3615, 1364-6893
- Tipo:
- Article
- Páginas:
- 218-220
- PubMed:
- 24484391
- Factor de Impacto:
- 0,416 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
JOURNAL OF OBSTETRICS AND GYNAECOLOGY TAYLOR & FRANCIS INC
Citas Recibidas en Web of Science: 17
Documentos
- No hay documentos
Filiaciones
Keywords
- Angiogenesis; fetal growth restriction; sFlt-1; VEGF
Proyectos y Estudios Clínicos
APLICACION DE TECNICAS LAPLACIANAS PARA LA MONITORIZACION DE LA ACTIVIDAD ELECTRICA DEL MUSCULO LISO HUMANO:ENFASIS EN ELECTROHISTEROGRAMA (LAMOHIS)
Investigador Principal: ALFREDO JOSÉ PERALES MARÍN
LAMOHIS PLAN NACIONAL I+D+I 2008-2011 . 2010
CON-CIENCIA-YV: PILDORAS DE SALUD
FCT-13-7457_FECYT_2013 . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
ESTUDIO PROSPECTIVO, DE SEGUIMIENTO, DE NIÑOS DE 23 A 25 MESES, NACIDOS DE MADRES QUE RECIBIERON CAPROATO DE HIDROXIPROGESTERONA INYECTABLE, 250 MG/ML O VEHICULO, PARA LA PREVENCION DEL PARTO PREMATURO.
Investigador Principal: ALFREDO JOSÉ PERALES MARÍN
17P-FU-004 . 2012
Cita
BORRAS D,PERALES A,RUIZ N,PERALES A. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated with intrauterine growth restriction. J Obstet Gynaecol. 2014. 34. (3):p. 218-220. IF:0,551. (4).